Clopidogrel Bisulfate/Aspirin

硫酸氢氯吡格雷/阿司匹林

Report date: 2026/05/26 20:00:28

Base Information

Drug NameClopidogrel Bisulfate/Aspirin
Drug Alias Name氯吡格雷/阿司匹林Clopidogrel hydrogensulfate/acetylsalicylic acid阿司匹林/氯吡格雷Clopidogrel Hydrogen Sulfate/Acetylsalicylic AcidClopidogrel hydrogen sulfate/Aspirin +[17] 
ClassificationSmall molecules
Mechanisms of ActionPurinergic receptor P2Y12 antagonistsCyclooxygenases inhibitors
TargetsCyclooxygenasesPurinergic receptor P2Y12
Therapy Area/IndicationsThrombosisEmbolismAtherosclerosis +[8] 
Global Approved IndicationsThrombosisAtherosclerosisMyocardial Infarction +[5] 
Approved Indications in ChinaAtherosclerosis
Original Approved Country/TerritorySingapore
Original Approved Date2008/01/01
Country/TerritorySingaporeAustraliaFrance +[7] 
CombinationsYes Clopidogrel BisulfateAspirin
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi AventisSanofiSanofi Winthrop Industrie SA +[4] 
Inactive CompaniesDong-A ST Co LtdYuhan Corp
Active IndicationsThrombosisAtherosclerosisMyocardial Infarction +[5] 
Inactive IndicationsEmbolismIschemic Attack, TransientBrain Infarction

Other Information

ATC CodeB01AC30
Related LinksKEGG